Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease caused by tuberous sclerosis complex 1/2 (TSC1/2) gene mutations in pulmonary mesenchymal cells, resulting in activation of the mechanistic target of rapamycin complex 1 (mTORC1). A subset of patients with LAM develop pulmonary vascular remodeling and pulmonary hypertension. Little, however, is known regarding how LAM cells communicate with endothelial cells (ECs) to trigger vascular remodeling. In end-stage LAM lung explants, we identified EC dysfunction characterized by increased EC proliferation and migration, defective angiogenesis, and dysmorphic endothelial tube network formation. To model LAM disease, we used an mTORC1 gain-of-function mouse model with a Tsc2 KO (Tsc2KO) specific to lung mesenchyme (Tbx4LME-CreTsc2fl/fl), similar to the mesenchyme-specific genetic alterations seen in human disease. As early as 8 weeks of age, ECs from mice exhibited marked transcriptomic changes despite an absence of morphological changes to the distal lung microvasculature. In contrast, 1-year-old Tbx4LME-CreTsc2fl/fl mice spontaneously developed pulmonary vascular remodeling with increased medial thickness. Single-cell RNA-Seq of 1-year-old mouse lung cells identified paracrine ligands originating from Tsc2KO mesenchyme, which can signal through receptors in arterial ECs. These ECs had transcriptionally altered genes including those in pathways associated with blood vessel remodeling. The proposed pathophysiologic mesenchymal ligand–EC receptor crosstalk highlights the importance of an altered mesenchymal cell/EC axis in LAM and other hyperactive mTORC1–driven diseases. Since ECs in patients with LAM and in Tbx4LME-CreTsc2fl/fl mice did not harbor TSC2 mutations, our study demonstrates that constitutively active mTORC1 lung mesenchymal cells orchestrated dysfunctional EC responses that contributed to pulmonary vascular remodeling.
The FDA‐approved Renuvion cold plasma device is currently used for dermal skin tightening procedures and subdermal tightening after liposuction. Anecdotally, patients report improved tissue healing outcomes following treatment. The most likely explanation for this is plasma‐generated reactive species which are inflammatory but also activate cellular signaling pathways, stimulate antioxidant responses, and activate immune cells. In this study, we aimed to determine the immediate and long‐term molecular effects of a single plasma treatment on surgically injured muscle and the soft tissue envelope. We used RNA sequencing, histology, and immunohistochemistry to determine changes to the tissue following treatment. Neutrophils and mast cells rapidly mobilize 6 h after treatment in conjunction with an upregulated cellular antioxidant response. Additionally, genes identified by RNAseq indicate upregulated pro‐regenerative muscle‐tissue‐protective gene transcripts and downregulated apoptotic pathway transcripts in the muscle tissue 6 h after treatment. The histology and RNAseq results from 4‐ and 14‐days post plasma treatment indicate that these early inflammatory and antioxidant events drive muscle regeneration to skew toward myogenic differentiation over adipogenesis. Thus, we conclude that a single plasma treatment results in an immediate inflammatory and antioxidant response that enhances long‐term muscle fiber repair through reduced adipogenesis.
Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify new targets for the development of curative LAM treatments. Nitazoxanide (NTZ) is an orally bioavailable antiprotozoal small molecule drug approved for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in children and adults, with a demonstrated mTORC1 inhibitory effect in several human cell lines. NTZ’s excellent safety profile characterized by its more than 20 years of clinical use makes it a promising candidate for repurposing. Our rationale for this study was to further investigate NTZ’s effect using in vitro and in vivo LAM models and to elucidate the underlying molecular mechanism beyond mTORC1 inhibition. For this purpose, we investigated cell proliferation, cell viability, and changes in protein phosphorylation and expression in primary human cell cultures derived from LAM lung samples before translating our results into a syngeneic mouse model utilizing Tsc2-null cells. NTZ reduced cell growth for all tested cell lines at a dose of about 30 µM. Lower doses than that had no effect on cell viability, but doses above 45 µM lowered the viability by about 10 to 15% compared to control. Interestingly, our western blot revealed no inhibition of mTORC1 and only a mild effect on active ß-Catenin. Instead, NTZ had a pronounced effect on reducing pAkt. In the mouse model, prophylactic NTZ treatment via the intraperitoneal and oral routes had some effects on reducing lung lesions and improving body weight retention, but the results remain inconclusive.
Alzheimer's disease (AD) is a progressive neurodegenerative disease which has pathologies linked to accumulation of A[beta] plaques in the brain. Despite being prevalent on a global scale, there remains no cure and few treatments for the disease. A drug treatment which interferes with underlying causes of AD is badly needed. Here we explore the ability of tabersonine, an indole alkaloid, and several tabersonine derivatives to interfere with A[beta] deposition in our well-characterized Drosophila melanogaster model of AD. Our results suggest that while tabersonine shows some ability to improve motor function in our model, its derivatives can provide an even greater rescue effect. Screening of several derivative compounds led to the identification of a compound known as "Shelley" which appeared to have excellent anti-AD activity. Treatment with "Shelley" results not only in a rescue of motor defects in AD model organisms to levels undiscernible from healthy organisms, but also a significant decrease in the number of A[beta]-42 fragments detectable in the brain. Tabersonine and its derivatives show great promise in our model at being able to rescue biochemical and behavioral effects of AD by targeting underlying causes, and we suggest that they may prove to be therapeutically useful with further study and characterization.